Industry note
AI Visibility for Digital Health Companies: How Telehealth and Health Tech Platforms Earn AI Citations
Digital health companies compete for billion-dollar health system contracts, but most are invisible in the AI-generated answers that now shape vendor shortlists. Here is how to fix that.
Updated May 18, 2026
Digital health AI visibility is the gap between building a real health technology product and being the company that AI systems cite when a hospital CIO, health plan executive, or clinical informaticist asks which platforms are worth evaluating. In 2026, that gap is where deals are won or lost before a single demo is scheduled.
The mechanism is straightforward. Health system buyers and their advisory teams now use ChatGPT, Perplexity, and Google AI Overviews to pre-screen vendor categories. They ask which telehealth platforms have proven clinical outcomes, which remote patient monitoring tools integrate with Epic, which behavioral health platforms reduce documentation burden. The answers are synthesized from trusted editorial and research sources. Companies that appear in those sources get shortlisted. Companies that do not get filtered out before the procurement conversation begins.
This matters more in digital health than in most technology categories because the trust threshold is structurally higher. The FDA has now authorized over 1,200 AI-enabled medical devices, creating a crowded landscape where buyer confusion favors the brands that show up with credible third-party validation. FDA AI/ML-Enabled Medical Devices Forrester's 2026 Healthcare CX Platform Wave confirmed the pattern: the market is moving fast but unevenly, and the companies that combine genuine product capability with external editorial proof are pulling ahead. Forrester Wave: CX Platforms For Healthcare, Q1 2026
Why digital health is harder than most categories
Digital health has three problems that make AI visibility more difficult and more important than in standard SaaS.
First, the regulatory environment is dense. HIPAA compliance, FDA regulatory pathways, clinical evidence standards, and state-by-state telehealth licensing create a web of constraints that every legitimate vendor must navigate. AI systems are sensitive to this complexity. They reward content that demonstrates regulatory fluency and penalize generic health-tech claims that sound like marketing rather than institutional understanding.
Second, the evidence bar is rising. Health system buyers increasingly demand randomized controlled trials, quasi-experimental designs, or at minimum real-world evidence before evaluating digital health tools. Eleos Health's $60 million Series C, for example, was explicitly tied to an RCT showing its AI platform improved progress note submission times by over 80 percent while doubling client engagement. VentureBeat That kind of evidence is exactly what AI systems cite because it originates from credible sources and carries specific, verifiable claims.
Third, the buyer journey is long and committee-driven. A hospital system evaluating a telehealth platform might involve clinical informatics, IT security, compliance, finance, and clinical operations. Each stakeholder runs independent research. If your company is missing from the AI-generated summaries any one of them encounters, you risk being eliminated by a single committee member's search.
The result is a market where capital is flowing freely but visibility is unevenly distributed. Grow Therapy reached a $3 billion valuation with its $150 million Series D. Bloomberg Tandem Technology hit a $1 billion valuation for AI-powered prescriptions. Bloomberg Lotus Health raised $35 million to build an AI doctor with full licensure in all 50 states. TechCrunch Ease Health emerged from stealth with $41 million from a16z for behavioral health infrastructure. VentureBeat Capital validates the market. But capital does not guarantee that AI systems will cite you when a buyer asks the category question.
Where the citations come from
Not every publication helps equally. For digital health, the highest-value sources fall into three tiers, each serving a different function in the buyer's AI-assisted research.
| Publication tier | Examples | What it does for AI visibility |
|---|---|---|
| Tier 1 business/tech press | Forbes, TechCrunch, Business Insider, Fast Company | Establishes baseline vendor credibility across buyer types |
| Healthcare trade publications | STAT News, Fierce Healthcare, MedCity News, Healthcare IT News | Validates clinical and operational fluency with institutional buyers |
| Academic and regulatory sources | Nature Digital Medicine, arXiv, FDA databases, peer-reviewed journals | Provides evidence-grade citations AI systems weight most heavily |
The third tier is where digital health diverges from other categories. A peer-reviewed study in Nature Digital Medicine or a clinical trial published on arXiv carries citation weight that no amount of trade press can match. Alberta Health Services deployed an open-source AI clinical documentation tool across 105 urban and rural facilities at under $30 per physician per month, a finding published as primary research that any AI system can cite as evidence of feasibility and cost. arXiv:2603.23513 That kind of research is the raw material AI engines use when they build answers about what works in digital health.
The trap is thinking that product announcements and funding press releases are sufficient. They are not. A TechCrunch funding story gets you one news cycle. A published clinical outcome study gets cited indefinitely.
A 90-day program for digital health AI visibility
Days 1 to 30: build the clinical evidence narrative
Identify the single strongest piece of evidence your company has for clinical or operational impact. It might be an RCT, a retrospective analysis, a deployment study, or a cost-effectiveness comparison. Package it in a form that can survive editorial scrutiny: specific outcomes, named methodology, anonymized institutional context.
If you have no evidence, this is the step where most digital health companies stall. The fix is not to fake it. The fix is to design a study that can be completed within a reasonable timeframe and published credibly. Even a retrospective analysis of deployment data can be valuable if the methodology is sound.
Regulatory context matters here too. If your product has FDA authorization, that is a citable fact. If your platform meets specific HIPAA requirements that your competitors do not, document that distinction. Compliance facts are boring to marketers but valuable to both health system buyers and AI systems because they are specific and verifiable.
Days 31 to 60: place the proof in the right outlets
With evidence in hand, the editorial placement sequence matters. Start with healthcare trade publications where the audience is clinical and operational decision-makers. STAT News, Fierce Healthcare, and Healthcare IT News reach the people who influence institutional procurement directly. Coverage here signals that your company understands the domain, not just the technology.
Then move to Tier 1 business and technology press. TechCrunch, Forbes, and Business Insider help with investor perception and broader market recognition. For digital health, this tier is most effective when the story is framed as a market insight or category shift, not a product announcement.
Days 61 to 90: verify the AI answer layer
Test the category queries your buyers actually ask. Prompt ChatGPT and Perplexity with questions like: "What are the best telehealth platforms for hospital systems?" or "Which digital health companies have published clinical evidence?" or "What behavioral health platforms reduce documentation burden?"
If your coverage is working, your company should begin appearing in the synthesized answers. If it is not appearing yet, the fix is usually not more content. It is better source selection: a published study, a more specific editorial angle, or a placement in a publication AI systems weight more heavily.
What this means for digital health teams
- If AI cannot cite you, the health system procurement committee will not see you in their pre-screening research.
- If the only citations are your own website, the signal is weak. Third-party editorial and clinical evidence is what sticks.
- If your competitors have published outcomes data and you have not, they will be cited and you will not.
- Funding announcements create awareness. Published evidence creates citation permanence.
Forrester projects healthcare will be one of the key sectors driving AI investment through 2030, with data governance, AI literacy training, and security hardware boosting technology spend across health systems. Forrester Global Tech Forecast, 2025 to 2030 That means health system buyers will use AI-assisted research for more vendor decisions, not fewer. The companies that build citation-grade editorial authority now will compound that advantage for years.
How Machine Relations fits
For digital health companies, Machine Relations is the discipline of building the editorial and research presence that AI systems use when health system buyers ask category-defining questions. The mechanism is the same as in other verticals: earn coverage in trusted publications, then make that coverage specific enough to cite. The difference in digital health is that the trust hierarchy extends beyond media outlets to include peer-reviewed research, regulatory databases, and clinical evidence repositories.
If you want the deeper framework, read What Is Machine Relations? and explore the Machine Relations research library. For the broader healthcare industry angle, see AI Visibility for Healthcare & MedTech and the healthcare-specific Machine Relations approach.
Key Takeaways
- Digital health AI visibility requires clinical evidence, not just media coverage.
- Health system buyers use AI tools to pre-screen vendors before procurement begins.
- Published outcomes data is the highest-value citation type in this category.
- Regulatory fluency in content signals credibility to both buyers and AI systems.
- The companies that build citation-grade editorial authority now will dominate AI-mediated discovery as health system AI adoption accelerates.
FAQ
How do digital health companies get cited by ChatGPT?
They earn coverage in trusted healthcare publications and publish clinical evidence that AI systems can cite. The most durable citations come from peer-reviewed studies, deployment data, and editorial features in outlets like STAT News, Fierce Healthcare, and Nature Digital Medicine.
Is AI visibility different from SEO for digital health?
Yes. SEO helps pages rank in search results. AI visibility determines whether a company appears in the synthesized answers AI systems generate when buyers research vendor categories. The two require different strategies: SEO optimizes for algorithms, AI visibility optimizes for citation-grade editorial authority.
Which publications matter most for digital health AI visibility?
STAT News, Fierce Healthcare, Healthcare IT News, and MedCity News for institutional buyers. Forbes, TechCrunch, and Business Insider for broader market credibility. Nature Digital Medicine, arXiv, and peer-reviewed journals for evidence-grade citations that AI systems weight most heavily.
Can digital health companies build AI visibility without publishing clinical trials?
Yes, but it is harder. Deployment studies, retrospective analyses, and regulatory compliance documentation all contribute to the editorial and evidence corpus AI systems draw from. Companies with published RCTs or real-world evidence have a significant advantage because those sources are cited more frequently and persistently.
How long does it take to build meaningful digital health AI visibility?
Plan for six to nine months. Healthcare buyers have long institutional memory and conservative evaluation processes. Credibility built through multiple placements in trusted publications and published evidence is more durable than a single high-profile hit.
Get a visibility audit to see where your digital health company currently appears in AI-generated answers for your category.